JP7850143B2 - Ｇ１３ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｑ ｔ細胞受容体 - Google Patents

Ｇ１３ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｑ ｔ細胞受容体

Info

Publication number
JP7850143B2
JP7850143B2 JP2023520143A JP2023520143A JP7850143B2 JP 7850143 B2 JP7850143 B2 JP 7850143B2 JP 2023520143 A JP2023520143 A JP 2023520143A JP 2023520143 A JP2023520143 A JP 2023520143A JP 7850143 B2 JP7850143 B2 JP 7850143B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
sequence
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023520143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544592A5 (enExample
JP2023544592A (ja
Inventor
レヴィン、ノーム
サード、フランク ジェイ． ロウリー、ザ
シー． パリア、ビーマン
エー． ローゼンバーグ、スティーヴン
ヨセフ、ラミ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2023544592A publication Critical patent/JP2023544592A/ja
Publication of JP2023544592A5 publication Critical patent/JP2023544592A5/ja
Application granted granted Critical
Publication of JP7850143B2 publication Critical patent/JP7850143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
JP2023520143A 2020-10-02 2021-10-01 Ｇ１３ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｑ ｔ細胞受容体 Active JP7850143B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086674P 2020-10-02 2020-10-02
US63/086,674 2020-10-02
PCT/US2021/053060 WO2022072760A1 (en) 2020-10-02 2021-10-01 Hla class ii-restricted dq t cell receptors against ras with g13d mutation

Publications (3)

Publication Number Publication Date
JP2023544592A JP2023544592A (ja) 2023-10-24
JP2023544592A5 JP2023544592A5 (enExample) 2024-10-09
JP7850143B2 true JP7850143B2 (ja) 2026-04-22

Family

ID=78676633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520143A Active JP7850143B2 (ja) 2020-10-02 2021-10-01 Ｇ１３ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｑ ｔ細胞受容体

Country Status (10)

Country Link
US (1) US20230365649A1 (enExample)
EP (1) EP4222169A1 (enExample)
JP (1) JP7850143B2 (enExample)
KR (1) KR20230084524A (enExample)
CN (1) CN116710111A (enExample)
AU (1) AU2021351710A1 (enExample)
CA (1) CA3194229A1 (enExample)
GB (1) GB2615010A (enExample)
TW (2) TW202229327A (enExample)
WO (1) WO2022072760A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4297785A4 (en) 2021-02-26 2025-01-22 New York University COMPOSITIONS AND METHODS USING ANTIBODIES FOR BINDING TO COVALENT PEPTIDE CONJUGATES
WO2025056685A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V
WO2026024602A2 (en) * 2024-07-22 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors against ras with g12d, g12v, g13d or q61r mutation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108395479A (zh) 2017-02-06 2018-08-14 高军 一种有关kras基因突变的t细胞受体
JP2018535647A (ja) 2015-09-15 2018-12-06 アメリカ合衆国 Ｈｌａ−ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
WO2019060349A1 (en) 2017-09-20 2019-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED
WO2019112941A1 (en) 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
JP2019527555A (ja) 2016-08-02 2019-10-03 アメリカ合衆国 抗ｋｒａｓ−ｇ１２ｄ ｔ細胞受容体
WO2020037239A1 (en) 2018-08-16 2020-02-20 Neon Therapeutics, Inc. T cell receptor constructs and uses thereof
WO2020154617A1 (en) 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
JP2023528112A (ja) 2020-02-12 2023-07-04 アメリカ合衆国 Ｇ１２ｄ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US20100286143A1 (en) * 2009-04-24 2010-11-11 Dora Dias-Santagata Methods and materials for genetic analysis of tumors
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
CN118994363A (zh) * 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
MX2019003768A (es) * 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
WO2019069125A1 (en) * 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
CA3094468A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MX2020014243A (es) * 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020145222A1 (ja) * 2019-01-07 2020-07-16 地方独立行政法人神奈川県立病院機構 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬
US12325734B2 (en) * 2019-01-15 2025-06-10 Altor Bioscience Llc Human immunodeficiency virus-specific T cell receptors
WO2020191365A1 (en) * 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20230109318A1 (en) * 2020-02-24 2023-04-06 Oblique Therapeutics Ab Kras epitopes and antibodies
KR20210153539A (ko) * 2020-06-10 2021-12-17 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535647A (ja) 2015-09-15 2018-12-06 アメリカ合衆国 Ｈｌａ−ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
JP2019527555A (ja) 2016-08-02 2019-10-03 アメリカ合衆国 抗ｋｒａｓ−ｇ１２ｄ ｔ細胞受容体
CN108395479A (zh) 2017-02-06 2018-08-14 高军 一种有关kras基因突变的t细胞受体
WO2019060349A1 (en) 2017-09-20 2019-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED
WO2019112941A1 (en) 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
WO2020037239A1 (en) 2018-08-16 2020-02-20 Neon Therapeutics, Inc. T cell receptor constructs and uses thereof
WO2020154617A1 (en) 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
JP2023528112A (ja) 2020-02-12 2023-07-04 アメリカ合衆国 Ｇ１２ｄ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHARITOU, T., et al.，"TRANSCRIPTIONAL AND METABOLIC REWIRING OF COLORECTAL CANCER CELLS EXPRESSING THE ONCOGENIC KRAS(G13D) MUTATION."，BRITISH JOURNAL OF CANCER，2019年05月28日，Vol.121, No.1，pp.37-50，https://www.nature.com/articles/s41416-019-0477-7.pdf
IIIZUMI, S., et al.，"Identification of novel HLA clas II-restricted neoantigens derived from driver mutations."，CANCERS，2019年02月24日，Vol.11, No.2，266(pp.1-14)，DOI: 10.3390/cancers11020266

Also Published As

Publication number Publication date
KR20230084524A (ko) 2023-06-13
WO2022072760A1 (en) 2022-04-07
TW202229327A (zh) 2022-08-01
CA3194229A1 (en) 2022-04-07
GB202305617D0 (en) 2023-05-31
GB2615010A (en) 2023-07-26
EP4222169A1 (en) 2023-08-09
AU2021351710A9 (en) 2025-03-20
TW202540156A (zh) 2025-10-16
JP2023544592A (ja) 2023-10-24
AU2021351710A1 (en) 2023-06-08
CN116710111A (zh) 2023-09-05
US20230365649A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
JP7385566B2 (ja) 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP7832111B2 (ja) Ｇ１２ｄ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP7735285B2 (ja) Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP7850143B2 (ja) Ｇ１３ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｑ ｔ細胞受容体
JP7742354B2 (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
KR20210118865A (ko) G12r 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
US20230272038A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12d mutation
TWI900647B (zh) 識別p53中r273c或y220c突變的t細胞受體
US20230257440A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12v mutation
RU2849866C1 (ru) T-клеточные рецепторы, рестриктированные по hla класса i, против ras с мутацией g12d

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230623

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260410

R150 Certificate of patent or registration of utility model

Ref document number: 7850143

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150